<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650817</url>
  </required_header>
  <id_info>
    <org_study_id>RAD1901-106</org_study_id>
    <secondary_id>2015-003555-22</secondary_id>
    <secondary_id>L54809.042.15</secondary_id>
    <nct_id>NCT02650817</nct_id>
  </id_info>
  <brief_title>A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer</brief_title>
  <official_title>A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to visualize and quantify ER-binding sites during treatment with
      Elacestrant (RAD1901)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of RAD1901 treatment on the estrogen receptor (ER) expression and estradiol binding to the ER in lesions from patients with metastatic breast cancer (mBC)</measure>
    <time_frame>14 Days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of FES uptake after RAD1901 treatment to clinical response</measure>
    <time_frame>Every 8 weeks for to up 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines</measure>
    <time_frame>Every 8 weeks for to up 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability assessed in terms of adverse events, serious adverse events, ECG, physical examination, ECOG performance status, vital signs, and laboratory values</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of RAD1901 will be assessed at predefined intervals</measure>
    <time_frame>Every 28 days for up to 3 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Elacestrant (formerly RAD1901)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD1901</intervention_name>
    <description>RAD1901, a novel selective ER degrader (SERD)</description>
    <arm_group_label>Elacestrant (formerly RAD1901)</arm_group_label>
    <other_name>Elacestrant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patients with histologically-proven, ER-positive, human epidermal growth factor
             receptor 2 (HER2)-negative, locally advanced, inoperative, and/or mBC

          2. Tumor progression after ≥ 6 months of at least 1 line of hormonal systemic treatment
             (SERM, SERD, or aromatase inhibitor) in the metastatic setting

          3. Measurable disease according to RECIST criteria v1.1 or clinically evaluable disease

          4. Greater than or equal to 18 years of age

          5. Patients must be post-menopausal

          6. Life expectancy &gt;3 months

        Key Exclusion Criteria:

          1. Greater than 3 lines of endocrine therapy for metastatic disease.

          2. Prior anti-cancer treatment or investigational drug therapy within the following
             windows:

               1. Tamoxifen or fulvestrant therapy &lt; 42 days before 1st 18FES-PET scan

               2. Any other anti-cancer endocrine therapy &lt; 14 days before 1st dose of study drug

               3. Any chemotherapy &lt; 28 days before 1st dose of study drug

               4. Any investigational drug therapy &lt; 28 days or 3 half-lives (whichever is longer)
                  prior to the 1st dose of study drug 2. Patients with untreated or symptomatic
                  central nervous system (brain) metastases 3. Patients with known endometrial
                  disorders, including evidence of endometrial hyperplasia, dysfunctional uterine
                  bleeding, or cysts
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum (VUMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

